European Journal of Cancer

Article	Citations
The European cancer burden in 2020: Incidence and mortality estimates for 40 countries and 25 major cancers	330
Mortality in patients with cancer and coronavirus disease 2019: A systematic review and pooled analysis of 52 studies	254
Global, regional and national burden of primary liver cancer by subtype	172
Preoperative pembrolizumab combined with chemoradiotherapy for oesophageal squamous cell carcinoma (PALACE-1)	165
Skin cancer classification via convolutional neural networks: systematic review of studies involving human experts	148
Consensus on molecular imaging and theranostics in neuroendocrine neoplasms	144
European consensus-based interdisciplinary guideline for melanoma. Part 1: Diagnostics: Update 2022	134
European consensus-based interdisciplinary guideline for melanoma. Part 2: Treatment - Update 2022	131
Risk factors for Coronavirus Disease 2019 (COVID-19) severity and mortality among solid cancer patients and impact of the disease on anticancer treatment: A French nationwide cohort study (GCO-002 CAC	126
Evidence-based recommendations on categories for extent of resection in diffuse glioma	118
Comparative assessment of early mortality risk upon immune checkpoint inhibitors alone or in combination with other agents across solid malignancies: a systematic review and meta-analysis	117
Ultrasound-based deep learning radiomics in the assessment of pathological complete response to neoadjuvant chemotherapy in locally advanced breast cancer	116
Neoadjuvant therapy or upfront surgery for resectable and borderline resectable pancreatic cancer: A meta-analysis of randomised controlled trials	113
Evolution of low HER2 expression between early and advanced-stage breast cancer	108
Selenium stimulates the antitumour immunity: Insights to future research	106
The immune landscape of neuroblastoma: Challenges and opportunities for novel therapeutic strategies in pediatric oncology	106
Deficient mismatch repair/microsatellite unstable colorectal cancer: Diagnosis, prognosis and treatment	103
Late-onset and long-lasting immune-related adverse events from immune checkpoint-inhibitors: An overlooked aspect in immunotherapy	102
Clinical practice guidelines for BRCA1 and BRCA2 genetic testing	97
Gastrointestinal cancer classification and prognostication from histology using deep learning: Systematic review	95
Immunogenicity and risk of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection after Coronavirus Disease 2019 (COVID-19) vaccination in patients with cancer: a systematic review and	92
Tertiary lymphoid structures marker CXCL13 is associated with better survival for patients with advanced-stage bladder cancer treated with immunotherapy	91
Exosomes and exosomal RNAs in breast cancer: A status update	91
A systematic review and meta-analysis: the effect of active cancer treatment on severity of COVID-19	89
Avapritinib in unresectable or metastatic PDGFRA D842V-mutant gastrointestinal stromal tumours: Long-term efficacy and safety data from the NAVIGATOR phase I trial	86

Effect of concomitant medications with immune-modulatory properties on the outcomes of patients with advanced cancer treated with immune checkpoint inhibitors: development and validation of a novel pr	82
Applications of single-cell and bulk RNA sequencing in onco-immunology	79
Intratumour microbiome associated with the infiltration of cytotoxic CD8+ T cells and patient survival in cutaneous melanoma	78
Immune-based combinations for the treatment of metastatic renal cell carcinoma: a meta-analysis of randomised clinical trials	75
Diagnosis and treatment of Merkel cell carcinoma: European consensus-based interdisciplinary guideline – Update 2022	75
Sentinel lymph node biopsy and morbidity outcomes in early cervical cancer: Results of a multicentre randomised trial (SENTICOL-2)	75
Interleukin-6 blockade for prophylaxis and management of immune-related adverse events in cancer immunotherapy	71
Immune checkpoint inhibitors in treatment of soft-tissue sarcoma: A systematic review and meta-analysis	69
High-intensity statins are associated with improved clinical activity of PD-1 inhibitors in malignant pleural mesothelioma and advanced non-small cell lung cancer patients	69
Real world data of cemiplimab in locally advanced and metastatic cutaneous squamous cell carcinoma	69
Perspectives on natural compounds in chemoprevention and treatment of cancer: an update with new promising compounds	69
Lenvatinib, toripalimab plus hepatic arterial infusion chemotherapy in patients with high-risk advanced hepatocellular carcinoma: A biomolecular exploratory, phase II trial	67
Combining CNN-based histologic whole slide image analysis and patient data to improve skin cancer classification	66
Repurposing anticancer drugs for the management of COVID-19	65
Dutch Oncology COVID-19 consortium: Outcome of COVID-19 in patients with cancer in a nationwide cohort study	64
Explainable artificial intelligence in skin cancer recognition: A systematic review	62
Atezolizumab plus bevacizumab versus lenvatinib for unresectable hepatocellular carcinoma: a large real-life worldwide population	62
High mortality among hospital-acquired COVID-19 infection in patients with cancer: A multicentre observational cohort study	62
Updated efficacy and safety of KEYNOTE-224: a phase II study of pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib	61
Long-term safety of pembrolizumab monotherapy and relationship with clinical outcome: A landmark analysis in patients with advanced melanoma	61
Effect of corticosteroids on the outcome of patients with advanced non–small cell lung cancer treated with immune-checkpoint inhibitors	59
How to manage patients with corticosteroids in oncology in the era of immunotherapy?	58
Immune scores in colorectal cancer: Where are we?	58
Epidemiology of cutaneous melanoma and keratinocyte cancer in white populations 1943–2036	58
Definition of oligometastatic esophagogastric cancer and impact of local oligometastasis-directed treatment: A systematic review and meta-analysis	57
The Pan-Immune-Inflammation Value in microsatellite instability–high metastatic colorectal cancer patients treated with immune checkpoint inhibitors	56
Baseline co-medications may alter the anti-tumoural effect of checkpoint inhibitors as well as the risk of immune-related adverse events	56
Reproducible safety and efficacy of atezolizumab plus bevacizumab for HCC in clinical practice: Results of the AB-real study	56
Management of patients with advanced prostate cancer—metastatic and/or castration-resistant prostate cancer: Report of the Advanced Prostate Cancer Consensus Conference (APCCC) 2022	55
Generating human prostate cancer organoids from leukapheresis enriched circulating tumour cells	55
Evaluation of COVID-19 vaccine response in patients with cancer: An interim analysis	54
STK11/LKB1 and KEAP1 mutations in non-small cell lung cancer: Prognostic rather than predictive?	53
Therapeutic vaccines for breast cancer: Has the time finally come?	53
European trends in breast cancer mortality, 1980–2017 and predictions to 2025	53
Probiotic supplement attenuates chemotherapy-related cognitive impairment in patients with breast cancer: a randomised, double-blind, and placebo-controlled trial	52
A systematic review and recommendations on the use of plasma EBV DNA for nasopharyngeal carcinoma	52
CRYODESMO-O1: A prospective, open phase II study of cryoablation in desmoid tumour patients progressing after medical treatment	52
Pembrolizumab and maraviroc in refractory mismatch repair proficient/microsatellite-stable metastatic colorectal cancer – The PICCASSO phase I trial	51
Renal adverse effects of immune checkpoints inhibitors in clinical practice: ImmuNoTox study	51
Durvalumab therapy following chemoradiation compared with a historical cohort treated with chemoradiation alone in patients with stage III non–small cell lung cancer: A real-world multicentre study	51
SARS-CoV-2 vaccines for cancer patients: a call to action	50
Avelumab–cetuximab–radiotherapy versus standards of care in locally advanced squamous-cell carcinoma of the head and neck: The safety phase of a randomised phase III trial GORTEC 2017-01 (REACH)	50
Long-term prognostic significance of HER2-low and HER2-zero in node-negative breast cancer	49
Hematological immune related adverse events after treatment with immune checkpoint inhibitors	48
The first report on coronavirus disease 2019 (COVID-19) vaccine refusal by patients with solid cancer in Italy: Early data from a single-institute survey	48
Economic impact of avoidable cancer deaths caused by diagnostic delay during the COVID-19 pandemic: A national population-based modelling study in England, UK	48
European consensus-based interdisciplinary guideline for diagnosis and treatment of basal cell carcinoma—update 2023	48
Poziotinib for EGFR and HER2 exon 20 insertion mutation in advanced NSCLC: Results from the expanded access program	47
The concepts of rechallenge and retreatment with immune checkpoint blockade in melanoma patients	47
Tumour-infiltrating lymphocyte density is associated with favourable outcome in patients with advanced non–small cell lung cancer treated with immunotherapy	46

Therapy response and prognosis of patients with early breast cancer with low positivity for hormone receptors – An analysis of 2765 patients from neoadjuvant clinical trials	46
The BNT162b2 mRNA COVID-19 vaccine in adolescents and young adults with cancer: A monocentric experience	45
Efficacy and safety of high-dose lanreotide autogel in patients with progressive pancreatic or midgut neuroendocrine tumours: CLARINET FORTE phase 2 study results	45
The impact of ARID1A mutation on molecular characteristics in colorectal cancer	45
Treatment-related toxicity and improved outcome from immunotherapy in hepatocellular cancer: Evidence from an FDA pooled analysis of landmark clinical trials with validation from routine practice	45
Integration of deep learning-based image analysis and genomic data in cancer pathology: A systematic review	45
European PanCareFollowUp Recommendations for surveillance of late effects of childhood, adolescent, and young adult cancer	44
Transplant rejections associated with immune checkpoint inhibitors: A pharmacovigilance study and systematic literature review	44
A benchmark for neural network robustness in skin cancer classification	44
Identification of breast cancer patients with pathologic complete response in the breast after neoadjuvant systemic treatment by an intelligent vacuum-assisted biopsy	44
Prognostic effect of low-level HER2 expression in patients with clinically negative HER2 status	44
Immune checkpoint inhibitors for cancer and venous thromboembolic events	43
A randomised trial of 4- versus 12-weekly administration of bone-targeted agents in patients with bone metastases from breast or castration-resistant prostate cancer	43
Effects of concomitant administration of anticancer agents and apixaban or dalteparin on recurrence and bleeding in patients with cancer-associated venous thromboembolism	43
COVID-19 vaccines in adult cancer patients with solid tumours undergoing active treatment: Seropositivity and safety. A prospective observational study in Italy	43
Osimertinib as first-line treatment for advanced epidermal growth factor receptor mutation–positive non–small-cell lung cancer in a real-world setting (OSI-FACT)	43
Long-term follow-up of blinatumomab in patients with relapsed/refractory Philadelphia chromosome–positive B-cell precursor acute lymphoblastic leukaemia: Final analysis of ALCANTARA study	43
Association between BRCA2 alterations and intraductal and cribriform histologies in prostate cancer	43
Poly (ADP-ribose) polymerase inhibitors in solid tumours: Systematic review and meta-analysis	42
Third dose of anti-SARS-CoV-2 vaccine for patients with cancer: Should humoral responses be monitored? A position article	41
Bridging the Age Gap in breast cancer: Impact of chemotherapy on quality of life in older women with early breast cancer	41
Pseudoprogression in patients treated with immune checkpoint inhibitors for microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer	41
Phase II and biomarker study of programmed cell death protein 1 inhibitor nivolumab and metronomic cyclophosphamide in paediatric relapsed/refractory solid tumours: Arm G of AcSé-ESMART, a trial of th	41
The determinants of very severe immune-related adverse events associated with immune checkpoint inhibitors: A prospective study of the French REISAMIC registry	41
Pathological complete response, long-term outcomes, and recurrence patterns in HER2-low versus HER2-zero breast cancer after neoadjuvant chemotherapy	41
Efficacy and safety of BNT162b2 vaccination in patients with solid cancer receiving anticancer therapy – a single centre prospective study	40
Combining immune checkpoint inhibitors with chemotherapy in advanced solid tumours: A review	40
Sex-differences in symptoms and functioning in >5000 cancer survivors: Results from the PROFILES registry	40
Circulating tumour DNA as a biomarker in resectable and irresectable stage IV colorectal cancer; a systematic review and meta-analysis	40
Deep learning approach to predict sentinel lymph node status directly from routine histology of primary melanoma tumours	40
Meta-analysis of prospective studies evaluating breast cancer detection and interval cancer rates for digital breast tomosynthesis versus mammography population screening	40
Deep learning can predict lymph node status directly from histology in colorectal cancer	40
Second Paediatric Strategy Forum for anaplastic lymphoma kinase (ALK) inhibition in paediatric malignancies	40
Determinants of enhanced vulnerability to coronavirus disease 2019 in UK patients with cancer: a European study	39
The effects of antibiotics on the efficacy of immune checkpoint inhibitors in patients with non–small-cell lung cancer differ based on PD-L1 expression	39
New cancer cases at the time of SARS-Cov2 pandemic and related public health policies: A persistent and concerning decrease long after the end of the national lockdown	39
A phase I/Ib study of regorafenib and nivolumab in mismatch repair proficient advanced refractory colorectal cancer	39
Risk factors and outcomes in children with high-risk B-cell precursor and T-cell relapsed acute lymphoblastic leukaemia: combined analysis of ALLR3 and ALL-REZ BFM 2002 clinical trials	38
Defining the role of real-world data in cancer clinical research: The position of the European Organisation for Research and Treatment of Cancer	38
Hepatocellular and extrahepatic cancers in non-alcoholic fatty liver disease: A systematic review and meta-analysis	38
Cancer survivorship: Reproductive health outcomes should be included in standard toxicity assessments	38
D2 dissection improves disease-specific survival in advanced gastric cancer patients: 15-year follow-up results of the Italian Gastric Cancer Study Group D1 versus D2 randomised controlled trial	38
COVID-19: Third dose booster vaccine effectiveness against breakthrough coronavirus infection, hospitalisations and death in patients with cancer: A population-based study	38
Phase I/II trial of palbociclib, pembrolizumab and letrozole in patients with hormone receptor-positive metastatic breast cancer	38
Phase I dose-escalation study of NBTXR3 activated by intensity-modulated radiation therapy in elderly patients with locally advanced squamous cell carcinoma of the oral cavity or oropharynx	38
A phase II study of monalizumab in patients with recurrent/metastatic squamous cell carcinoma of the head and neck: The I1 cohort of the EORTC-HNCG-1559 UPSTREAM trial	37
Pre-therapeutic UGT1A1 genotyping to reduce the risk of irinotecan-induced severe toxicity: Ready for prime time	37
A phase I dose-escalation study of oxaliplatin delivered via a laparoscopic approach using pressurised intraperitoneal aerosol chemotherapy for advanced peritoneal metastases of gastrointestinal tract	37
Access and quality of biomarker testing for precision oncology in Europe	37
Long-term clinical activity, safety and patient-reported quality of life for emactuzumab-treated patients with diffuse-type tenosynovial giant-cell tumour	37
Real-world evidence of cabozantinib in patients with metastatic renal cell carcinoma: Results from the CABOREAL Early Access Program	37
Tumour-agnostic circulating tumour DNA analysis for improved recurrence surveillance after resection of colorectal liver metastases: A prospective cohort study	37
Cardiotoxicity of immune checkpoint inhibitors: A systematic review and meta-analysis of randomised clinical trials	37
Therapeutic drug monitoring in oncology: International Association of Therapeutic Drug Monitoring and Clinical Toxicology consensus guidelines for imatinib therapy	37
Immune checkpoint inhibitor–associated sarcoidosis: A usually benign disease that does not require immunotherapy discontinuation	37
Trastuzumab emtansine for patients with non–small cell lung cancer positive for human epidermal growth factor receptor 2 exon-20 insertion mutations	36
Baseline total metabolic tumour volume on 2-deoxy-2-[18F]fluoro-d-glucose positron emission tomography-computed tomography as a promising biomarker in patients with advanced non–small cell lung cancer	36
Conversion strategies with chemotherapy plus targeted agents for colorectal cancer liver-only metastases: A systematic review	36
Regional lymphadenopathy following COVID-19 vaccination: Literature review and considerations for patient management in breast cancer care	36
OlympiAD extended follow-up for overall survival and safety: Olaparib versus chemotherapy treatment of physician's choice in patients with a germline BRCA mutation and HER2-negative metastatic breast	36
Completion of radical hysterectomy does not improve survival of patients with cervical cancer and intraoperatively detected lymph node involvement: ABRAX international retrospective cohort study	36
Carvedilol blocks neural regulation of breast cancer progression in vivo and is associated with reduced breast cancer mortality in patients	36
ACCELERATE – Five years accelerating cancer drug development for children and adolescents	35
Predictors of poor seroconversion and adverse events to SARS-CoV-2 mRNA BNT162b2 vaccine in cancer patients on active treatment	35
SARS-CoV-2 in children with cancer or after haematopoietic stem cell transplant: An analysis of 131 patients	35
EORTC consensus recommendations for the treatment of mycosis fungoides/Sézary syndrome – Update 2023	35
Nivolumab plus docetaxel in patients with chemotherapy-naïve metastatic castration-resistant prostate cancer: results from the phase II CheckMate 9KD trial	34
Development and validation of a pancreatic cancer risk model for the general population using electronic health records: An observational study	34
Robustness of convolutional neural networks in recognition of pigmented skin lesions	34
Impact of COVID-19 and suspension of colorectal cancer screening on incidence and stage distribution of colorectal cancers in the Netherlands	34
Gemcitabine/nab-Paclitaxel versus FOLFIRINOX for palliative first-line treatment of advanced pancreatic cancer: A propensity score analysis	34
Identification of stage I/IIA melanoma patients at high risk for disease relapse using a clinicopathologic and gene expression model	34
Novel PD-1 inhibitor prolgolimab: expanding non-resectable/metastatic melanoma therapy choice	34
Androgen deprivation therapy and radiotherapy in intermediate-risk prostate cancer: A randomised phase III trial	34
Current strategies for intratumoural immunotherapy – Beyond immune checkpoint inhibition	33
Long-term efficacy update of crizotinib in patients with advanced, inoperable inflammatory myofibroblastic tumour from EORTC trial 90101 CREATE	33
Predicting 10-year survival after resection of colorectal liver metastases; an international study including biomarkers and perioperative treatment	33
Palbociclib plus letrozole versus placebo plus letrozole in Asian postmenopausal women with oestrogen receptor–positive/human epidermal growth factor receptor 2–negative advanced breast cancer: Primar	33
Rare use of patient-reported outcomes in childhood cancer clinical trials – a systematic review of clinical trial registries	33
Evidence-based management of COVID-19 in cancer patients: Guideline by the Infectious Diseases Working Party (AGIHO) of the German Society for Haematology and Medical Oncology (DGHO)	33

2021 update of the AGIHO guideline on evidence-based management of COVID-19 in patients with cancer regarding diagnostics, viral shedding, vaccination and therapy	33
Machine learning reveals a PD-L1–independent prediction of response to immunotherapy of non-small cell lung cancer by gene expression context	33
Osimertinib versus osimertinib plus chemotherapy for non–small cell lung cancer with EGFR (T790M)-associated resistance to initial EGFR inhibitor treatment: An open-label, randomised phase 2 clinical	32
Bridging the age gap in breast cancer. Impacts of omission of breast cancer surgery in older women with oestrogen receptor positive early breast cancer. A risk stratified analysis of survival outcomes	32
Circulating tumor DNA is a prognostic marker of tumor recurrence in stage II and III colorectal cancer: multicentric, prospective cohort study (ALGECOLS)	32
Pathological complete response rate and disease-free survival after neoadjuvant chemotherapy in patients with HER2-low and HER2-0 breast cancers	32
Autologous dendritic cells pulsed with allogeneic tumour cell lysate induce tumour-reactive T-cell responses in patients with pancreatic cancer: A phase I study	32
Efficacy and safety of GLS-010 (zimberelimab) in patients with relapsed or refractory classical Hodgkin lymphoma: A multicenter, single-arm, phase II study	32
Exposure to artificial light at night: A common link for obesity and cancer?	32
Response to brentuximab vedotin versus physician’s choice by CD30 expression and large cell transformation status in patients with mycosis fungoides: An ALCANZA sub-analysis	32
Coronary artery disease surveillance among childhood, adolescent and young adult cancer survivors: A systematic review and recommendations from the International Late Effects of Childhood Cancer Guide	32
Durvalumab consolidation in patients with unresectable stage III non-small cell lung cancer with driver genomic alterations	32
Informative censoring of surrogate end-point data in phase 3 oncology trials	31
Content validity of the EORTC quality of life questionnaire QLQ-C30 for use in cancer	31
Outcome of combination therapy using BRAF and MEK inhibitors among Asian patients with advanced melanoma: An analysis of 112 cases	31
Exceptional tumour responses to fasting-mimicking diet combined with standard anticancer therapies: A sub-analysis of the NCT03340935 trial	31
Impact of COVID-19 on healthcare organisation and cancer outcomes	31
A randomised phase II study of oxaliplatin/5-FU (mFOLFOX) versus irinotecan/5-FU (mFOLFIRI) chemotherapy in locally advanced or metastatic biliary tract cancer refractory to first-line gemcitabine/cis	31
Triplet combination of durvalumab, tremelimumab, and paclitaxel in biliary tract carcinomas: Safety run-in results of the randomized IMMUNOBIL PRODIGE 57 phase II trial	31
Dynamic changes in circulating PD-1+CD8+ T lymphocytes for predicting treatment response to PD-1 blockade in patients with non-small-cell lung cancer	30
Understanding the organ tropism of metastatic breast cancer through the combination of liquid biopsy tools	30
Methylation biomarkers for early cancer detection and diagnosis: Current and future perspectives	30
Clinical practice guideline for the prevention of oral and oropharyngeal mucositis in pediatric cancer and hematopoietic stem cell transplant patients: 2021 update	30
Current perspectives for SARS-CoV-2 vaccination efficacy improvement in patients with active treatment against cancer	30
Anthracycline-induced cardiotoxicity — are we about to clear this hurdle?	30
High tumor mutational burden (TMB) identifies a microsatellite stable pancreatic cancer subset with prolonged survival and strong anti-tumor immunity	30
Semiquantitative evaluation of lymph-vascular space invasion in patients affected by endometrial cancer: Prognostic and clinical implications	30
Definitions and treatment of oligometastatic oesophagogastric cancer according to multidisciplinary tumour boards in Europe	30
CDK12 inhibition enhances sensitivity of HER2+ breast cancers to HER2-tyrosine kinase inhibitor via suppressing PI3K/AKT	30
Immunosuppressive profiles in liquid biopsy at diagnosis predict response to neoadjuvant chemotherapy in triple-negative breast cancer	30
Adjuvant stereotactic body radiotherapy after marginal resection for hepatocellular carcinoma with microvascular invasion: A randomised controlled trial	29
Minimally important differences for interpreting EORTC QLQ-C30 change scores over time: A synthesis across 21 clinical trials involving nine different cancer types	29
Renin–angiotensin–aldosterone system inhibitors and survival in patients with hypertension treated with immune checkpoint inhibitors	29
Phase I dose-escalation study of endoscopic intratumoral injection of OBP-301 (Telomelysin) with radiotherapy in oesophageal cancer patients unfit for standard treatments	29
Rucaparib in patients presenting a metastatic breast cancer with homologous recombination deficiency, without germline BRCA1/2 mutation	29
Predicting immunotherapy outcomes under therapy in patients with advanced NSCLC using dNLR and its early dynamics	29
Artificial intelligence–powered programmed death ligand 1 analyser reduces interobserver variation in tumour proportion score for non–small cell lung cancer with better prediction of immunotherapy res	29
UGT1A1 genotype-guided dosing of irinotecan: A prospective safety and cost analysis in poor metaboliser patients	29
Targeted inhibitors and antibody immunotherapies: Novel therapies for paediatric leukaemia and lymphoma	29
Chemotherapy after immune checkpoint inhibitor failure in metastatic melanoma: a retrospective multicentre analysis	29
The potential of combined shear wave and strain elastography to reduce unnecessary biopsies in breast cancer diagnostics – An international, multicentre trial	29
A review of lifestyle and environment risk factors for pancreatic cancer	29
Disseminated tumour cells from the bone marrow of early breast cancer patients: Results from an international pooled analysis	29
Comparative efficacy of novel combination strategies for unresectable hepatocellular carcinoma: A network metanalysis of phase III trials	29
Impact of lung metastases on overall survival in the phase 3 SELECT study of lenvatinib in patients with radioiodine-refractory differentiated thyroid cancer	29
Clinical outcomes, Kadish-INSICA staging and therapeutic targeting of somatostatin receptor 2 in olfactory neuroblastoma	29
Bipolar androgen therapy sensitizes castration-resistant prostate cancer to subsequent androgen receptor ablative therapy	28
First-line liposomal irinotecan with oxaliplatin, 5-fluorouracil and leucovorin (NALIRIFOX) in pancreatic ductal adenocarcinoma: A phase I/II study	28
Resistance profiles of anaplastic lymphoma kinase tyrosine kinase inhibitors in advanced non–small-cell lung cancer: a multicenter study using targeted next-generation sequencing	28
Third dose of SARS-CoV-2 vaccination in hemato-oncological patients and health care workers: immune responses and adverse events – a retrospective cohort study	28
Determinants of disease-specific survival in patients with and without metastatic pheochromocytoma and paraganglioma	28
Skin lesions of face and scalp – Classification by a market-approved convolutional neural network in comparison with 64 dermatologists	28
Progression-free survival and safety at 3.5 years of follow-up: results from the randomised phase 3 PRIMA/ENGOT-OV26/GOG-3012 trial of niraparib maintenance treatment in patients with newly diagnosed	28
The role of tyrosine kinase inhibitors in the treatment of HER2+ metastatic breast cancer	28
Development and validation of circulating tumour cell enumeration (Epic Sciences) as a prognostic biomarker in men with metastatic castration-resistant prostate cancer	27
Persistent immune-related adverse events after cessation of checkpoint inhibitor therapy: Prevalence and impact on patients' health-related quality of life	27
Paediatric Strategy Forum for medicinal product development of chimeric antigen receptor T-cells in children and adolescents with cancer	27
Antibody titres before and after a third dose of the SARS-CoV-2 BNT162b2 vaccine in patients with cancer	27
STK11 alterations in the pan-cancer setting: prognostic and therapeutic implications	27
Real-world efficacy of anti-PD-1 antibody or combined anti-PD-1 plus anti-CTLA-4 antibodies, with or without radiotherapy, in advanced mucosal melanoma patients: A retrospective, multicenter study	27
Maintenance olaparib plus bevacizumab in patients with newly diagnosed advanced high-grade ovarian cancer: Main analysis of second progression-free survival in the phase III PAOLA-1/ENGOT-ov25 trial	27
Infectious complications in patients treated with immune checkpoint inhibitors	27
Perioperative trastuzumab, capecitabine and oxaliplatin in patients with HER2-positive resectable gastric or gastro-oesophageal junction adenocarcinoma: NEOHX phase II trial	27
Preference for the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection in patients with HER2-positive early breast cancer (PHranceSCa): A randomised, open-label phase II st	27
Regorafenib–avelumab combination in patients with biliary tract cancer (REGOMUNE): a single-arm, open-label, phase II trial	27
Booster doses of COVID-19 vaccines for patients with haematological and solid cancer: a systematic review and individual patient data meta-analysis	26
The annual recurrence risk model for tailored surveillance strategy in patients with cervical cancer	26
Integration of quantitative imaging biomarkers in clinical trials for MR-guided radiotherapy: Conceptual guidance for multicentre studies from the MR-Linac Consortium Imaging Biomarker Working Group	26
Mutational profiles of primary pulmonary adenocarcinoma and paired brain metastases disclose the importance of KRAS mutations	26
A randomised phase II study of modified FOLFIRINOX versus gemcitabine plus nab-paclitaxel for locally advanced pancreatic cancer (JCOG1407)	26
Prospective evaluation of the prognostic value of immune-related adverse events in patients with non-melanoma solid tumour treated with PD-1/PD-L1 inhibitors alone and in combination with radiotherapy	26
First-line immune-checkpoint inhibitor combination therapy for chemotherapy-eligible patients with metastatic urothelial carcinoma: A systematic review and meta-analysis	26
Real-world outcomes associated with new cancer medicines approved by the Food and Drug Administration and European Medicines Agency: A retrospective cohort study	26
RAS as a positive predictive biomarker: focus on lung and colorectal cancer patients	26
Tobacco-related cancers in Europe: The scale of the epidemic in 2018	26
Darolutamide and health-related quality of life in patients with non-metastatic castration-resistant prostate cancer: An analysis of the phase III ARAMIS trial	26
Molecular testing of rhabdomyosarcoma in clinical trials to improve risk stratification and outcome: A consensus view from European paediatric Soft tissue sarcoma Study Group, Children's Oncology Grou	26
Non-parameningeal head and neck rhabdomyosarcoma in children, adolescents, and young adults: Experience of the European paediatric Soft tissue sarcoma Study Group (EpSSG) – RMS2005 study	25
Prognostic and predictive value of β-blockers in the EORTC 1325/KEYNOTE-054 phase III trial of pembrolizumab versus placebo in resected high-risk stage III melanoma	25
Risk and location of distant metastases in patients with locally advanced rectal cancer after total neoadjuvant treatment or chemoradiotherapy in the RAPIDO trial	25
HER2 mediates clinical resistance to the KRASG12C inhibitor sotorasib, which is overcome by co-targeting SHP2	25
The pathological significance of LOXL2 in pre-metastatic niche formation of HCC and its related molecular mechanism	25
Cracking the homologous recombination deficiency code: how to identify responders to PARP inhibitors	25
What should be done in terms of fertility preservation for patients with cancer? The French 2021 guidelines	25
Evaluation of pembrolizumab monotherapy in patients with previously treated advanced salivary gland carcinoma in the phase 2 KEYNOTE-158 study	25
Wilms tumour surveillance in at-risk children: Literature review and recommendations from the SIOP-Europe Host Genome Working Group and SIOP Renal Tumour Study Group	25
Response to systemic therapy in fumarate hydratase–deficient renal cell carcinoma	25
Implementation of paediatric precision oncology into clinical practice: The Individualized Therapies for Children with cancer program ‘iTHER’	25
First-in-child phase I/II study of the dual mTORC1/2 inhibitor vistusertib (AZD2014) as monotherapy and in combination with topotecan-temozolomide in children with advanced malignancies: arms E and F	25
Clinical impact of STK11 mutation in advanced-stage non-small cell lung cancer	25
Sequential therapies after atezolizumab plus bevacizumab or lenvatinib first-line treatments in hepatocellular carcinoma patients	24
The MUSES∗: a prognostic study on 1360 patients with sinonasal cancer undergoing endoscopic surgery-based treatment	24
A prospective multicentre trial on survival after Microwave Ablation VErsus Resection for Resectable Colorectal liver metastases (MAVERRIC)	24
Cancer survival in women diagnosed with pregnancy-associated cancer: An overview using nationwide registry data in Sweden 1970–2018	24
Study of the SARS-CoV-2-specific immune T-cell responses in COVID-19-positive cancer patients	24